Celyad Oncology SA
XBRU:CYAD

Watchlist Manager

Celyad Oncology SA

XBRU:CYAD

Watchlist

Dividends

Price: 0.65 EUR -2.99% Market Closed

Market Cap: 14.7m EUR

Have any thoughts about
Celyad Oncology SA?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

Add Price Alert

Price Target:

Last Price: 0.65 EUR

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

CYAD Alert

Celyad Oncology SA

0.65

-0.02 (-2.99%)

52 Week Range	0.2295 1
Price Target

We'll email you a reminder when the closing price reaches EUR.

Save Alert

Choose the stock you wish to monitor with a price alert.

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Celyad Oncology SA

What unique competitive advantages
does Celyad Oncology SA hold over its rivals?

What risks and challenges
does Celyad Oncology SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Celyad Oncology SA.

What unique competitive advantages
does Celyad Oncology SA hold over its rivals?

What risks and challenges
does Celyad Oncology SA face in the near future?

Has there been any significant insider trading activity
in Celyad Oncology SA recently?

Summarize the latest earnings call
of Celyad Oncology SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Celyad Oncology SA.

Provide P/S
for Celyad Oncology SA.

Provide P/E
for Celyad Oncology SA.

Provide P/OCF
for Celyad Oncology SA.

Provide P/FCFE
for Celyad Oncology SA.

Provide P/B
for Celyad Oncology SA.

Provide EV/S
for Celyad Oncology SA.

Provide EV/GP
for Celyad Oncology SA.

Provide EV/EBITDA
for Celyad Oncology SA.

Provide EV/EBIT
for Celyad Oncology SA.

Provide EV/OCF
for Celyad Oncology SA.

Provide EV/FCFF
for Celyad Oncology SA.

Provide EV/IC
for Celyad Oncology SA.

Show me price targets
for Celyad Oncology SA made by professional analysts.

What are the Revenue projections
for Celyad Oncology SA?

How accurate were the past Revenue estimates
for Celyad Oncology SA?

What are the Net Income projections
for Celyad Oncology SA?

How accurate were the past Net Income estimates
for Celyad Oncology SA?

What are the EPS projections
for Celyad Oncology SA?

How accurate were the past EPS estimates
for Celyad Oncology SA?

What are the EBIT projections
for Celyad Oncology SA?

How accurate were the past EBIT estimates
for Celyad Oncology SA?

Compare the revenue forecasts
for Celyad Oncology SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Celyad Oncology SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Celyad Oncology SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Celyad Oncology SA compared to its peers.

Compare the P/E ratios
of Celyad Oncology SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Celyad Oncology SA with its peers.

Analyze the financial leverage
of Celyad Oncology SA compared to its main competitors.

Show all profitability ratios
for Celyad Oncology SA.

Provide ROE
for Celyad Oncology SA.

Provide ROA
for Celyad Oncology SA.

Provide ROIC
for Celyad Oncology SA.

Provide ROCE
for Celyad Oncology SA.

Provide Gross Margin
for Celyad Oncology SA.

Provide Operating Margin
for Celyad Oncology SA.

Provide Net Margin
for Celyad Oncology SA.

Provide FCF Margin
for Celyad Oncology SA.

Show all solvency ratios
for Celyad Oncology SA.

Provide D/E Ratio
for Celyad Oncology SA.

Provide D/A Ratio
for Celyad Oncology SA.

Provide Interest Coverage Ratio
for Celyad Oncology SA.

Provide Altman Z-Score Ratio
for Celyad Oncology SA.

Provide Quick Ratio
for Celyad Oncology SA.

Provide Current Ratio
for Celyad Oncology SA.

Provide Cash Ratio
for Celyad Oncology SA.

What is the historical Revenue growth
over the last 5 years for Celyad Oncology SA?

What is the historical Net Income growth
over the last 5 years for Celyad Oncology SA?

What is the current Free Cash Flow
of Celyad Oncology SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Celyad Oncology SA.

EV/IC
Enterprise Value to IC

1.1

Current

0.5

Median

4.6

Industry

Higher than median

Lower than industry value

Enterprise Value to Invested Capital (EV/IC) ratio is a valuation multiple that measures the dollars in Enterprise Value for each dollar of capital invested by shareholders and lenders.

EV/IC

1.1

Enterprise Value

8.6m EUR

Invested Capital

8m EUR

All Countries

Forward Multiples

			Market Cap	EV/IC
BE		Celyad Oncology SA XBRU:CYAD	14.7m EUR	1.1
FR		Pharnext SCA OTC:PNEXF	6T USD	-1 413 880.6
US		Abbvie Inc NYSE:ABBV	320.1B USD	3.5
US		Amgen Inc NASDAQ:AMGN	150.5B USD	3.2
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	120.4B USD	10.8
US		Gilead Sciences Inc NASDAQ:GILD	113.8B USD	2.2
US	E	Epizyme Inc F:EPE	94.1B EUR	861.8
AU		CSL Ltd ASX:CSL	135.4B AUD	2.9
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	82.9B USD	2.8
US	S	Seagen Inc F:SGT	39.3B EUR	18.4
NL		argenx SE XBRU:ARGX	34.5B EUR	23.4


BE		Celyad Oncology SA XBRU:CYAD	Average EV/IC: 93 1.1
FR		Pharnext SCA OTC:PNEXF	Negative Multiple: -1 413 880.6
US		Abbvie Inc NYSE:ABBV	3.5
US		Amgen Inc NASDAQ:AMGN	3.2
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	10.8
US		Gilead Sciences Inc NASDAQ:GILD	2.2
US	E	Epizyme Inc F:EPE	861.8
AU		CSL Ltd ASX:CSL	2.9
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	2.8
US	S	Seagen Inc F:SGT	18.4
NL		argenx SE XBRU:ARGX	23.4

EV/IC Forward Multiples

Forward EV/IC multiple is a version of the EV/IC ratio that uses forecasted invested capital for the EV/IC calculation. 1-Year, 2-Years, and 3-Years forwards use invested capital forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward

EV/IC

N/A

2-Years Forward

EV/IC

N/A

3-Years Forward

EV/IC

N/A

Celyad Oncology SA
XBRU:CYAD

EV/IC
Enterprise Value to IC

EV/IC Forward Multiples

See Also

Company

Help

Tools

Stocks

Celyad Oncology SA XBRU:CYAD

EV/IC Enterprise Value to IC

EV/IC Forward Multiples

See Also

Company

Help

Tools

Stocks

Celyad Oncology SA
XBRU:CYAD

EV/IC
Enterprise Value to IC